Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in China for its proprietary drug, tegileridine, indicated for the management of moderate to severe pain following abdominal surgery. This milestone marks the drug as the nation’s inaugural Category 1 opioid analgesic developed indigenously, highlighting a significant advancement in the field of pain management. Tegileridine functions as a μ opioid receptor (MOR)-biased small-molecule agonist, offering an alternative for postoperative pain relief.
In a related development, Trevena’s Olinvyk (oliceridine), a comparable product that gained approval in the US in 2020, was licensed by Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) and has recently been granted approval in China as of May 2023. The approval of these two drugs signifies a notable expansion in the therapeutic options available for patients grappling with postoperative pain, potentially enhancing clinical outcomes and providing much-needed relief.- Flcube.com
